Osaka and Ube, Japan, May 26, 2015 _ Mitsubishi Tanabe Pharma Corporation (President & Representative Director, CEO: Masayuki Mitsuka, hereinafter "Mitsubishi Tanabe Pharma") and Ube Industries, Ltd. (President & Representative Director: Yuzuru Yamamoto, hereinafter "Ube Industries") announced today that Mitsubishi Tanabe Pharma has received approval of a partial change of approved information (hereinafter "approval of a partial change") for TALION® Tablets and TALION® OD Tablets (generic name: bepotastine besilate), Anti-Allergic Agents. The partial change is related to additional pediatric indications (for children at least seven years of age).
Since its launch in October 2000 as a second-generation non-sedating anti-histamine, TALION® has been used in many medical institutions because of its excellent clinical effectiveness for adult allergic rhinitis, urticaria, and pruritus accompanying dermatitis (eczema/skin inflammation, prurigo, itching)with assurance of a high level of safety, and minimal effect on daily activities due to absence of impaired performance.*1
Clinical trials for children proved the same level of efficacy and safety as in adults. This led to the approval of a partial change and use in pediatric patients with allergic disease.
TALION® was discovered by Ube Industries and has been developed jointly by Mitsubishi Tanabe Pharma and Ube Industries. Mitsubishi Tanabe Pharma received approval for TALION® Tablets in 2000, and received approval for TALION® OD Tablets for additional formulation in 2007, and has since marketed the product.
Mitsubishi Tanabe Pharma and Ube Industries will contribute to a higher quality of life for patients by providing a new choice in the treatment of pediatric allergic disease.
